Concert
Pharmaceuticals, Inc. CNCE today announced that it has
initiated a Phase 1 multiple ascending dose clinical trial with CTP-656.
CTP-656 (deuterium-modified ivacaftor) is a novel, potentially
disease-modifying treatment for cystic fibrosis for use as monotherapy
as well as in combination with other CFTR modulators. Ivacaftor is
commercially available under the name Kalydeco®.
"CTP-656 has the potential to be an important new treatment, expanding
therapeutic options for the cystic fibrosis community," said James
Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals.
"We believe the development of CTP-656 as a once-daily dose could help
address adherence issues documented with the current standard of care by
offering a simplified treatment
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in